Acelive D 80mg/100mg Tablet
By Acelive D
Rx
10 Tablet in a Strip
Composition
Drotaverine(80mg) + Aceclofenac(100mg)
Manufacturer - Yodley Life Sciences Private Limited
S.C.O - 21, Old Ropar Road, Manimajra, Chandigarh-160101, India
Expires on or after
July, 2025
Acelive D 80mg/100mg Tablet requires caution when used by patients with liver disease. It is advisable to consult your doctor as dose adjustment may be necessary. Patients with severe liver disease are not recommended to use Acelive D 80mg/100mg Tablet. Regular monitoring of liver function tests is recommended for patients taking this medicine. If you have liver impairment or any concerns regarding your liver health, it is important to consult your doctor for proper guidance.
Acelive D 80mg/100mg Tablet should be used carefully if you have kidney disease. Adjusting the dosage may be necessary. It's better to consult your doctor as Acelive D 80mg/100mg Tablet is not recommended for those with severe kidney disease. Dose adjustment might also be needed if you have kidney impairment, so consulting your doctor for guidance is advisable.
It is unsafe to consume alcohol with Acelive D 80mg/100mg Tablet, as it may increase drowsiness and risk of stomach bleeding.
Acelive D 80mg/100mg Tablet can cause side effects that might impact driving ability, such as drowsiness and vertigo. Avoid driving or operating machinery if feeling drowsy or dizzy when taking Acelive D 80mg/100mg Tablet.
Acelive D 80mg/100mg Tablet may not be safe to use during pregnancy, as animal studies have shown potential harm to the developing baby. Your doctor will assess the benefits and risks before prescribing. Please consult your doctor if you have any concerns.
It is better to consult your doctor before using Acelive D 80mg/100mg Tablet.
Habit Forming | No |
Chemical Class | - |
Therapeutic Class | GASTRO INTESTINAL |
Action Class | - |
₹80
Inclusive of all taxes
Content verified by
Dr. Gowri Kulkarni
MBBS - General Medicine, DNB - Psychiatry, MRCGP [INT] Family Medicine, BSIC (BACP)
Last update on 18-Nov-2024